Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 70

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Duchenne muscular dystrophy

Recruiting

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Myotonic dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings S.A.

Clostridium difficile infection

Recruiting

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Vedanta Biosciences Inc.

Myelofibrosis+1

Recruiting

Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Cardiac failure

Recruiting

Study on Colchicine and Thiamine for Patients with Heart Failure from Ischemic Heart Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Acute lymphocytic leukaemia+4

Recruiting

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Malabsorption

Recruiting

Study on the Safety of ELGN-2112 for Preterm Infants with Intestinal Malabsorption

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Insulin Human
  • Sponsor:Elgan Pharma Ltd.

Anaplastic large cell lymphoma T- and null-cell types+1

Recruiting

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Neoplasm+1

Recruiting

Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Study on Pembrolizumab and Radiotherapy for Patients with High-Risk Soft Tissue Sarcoma in the Limbs

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.